Cisplatin-Induced Hearing Loss (CIHL) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Cisplatin-Induced Hearing Loss (CIHL) Emerging Therapy and TPP Insights

Thelansis's "Cisplatin-Induced Hearing Loss (CIHL) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Cisplatin-Induced Hearing Loss (CIHL) Overview

Cisplatin-induced hearing loss (CIHL) is an irreversible, dose-dependent sensorineural ototoxicity caused by drug accumulation within cochlear outer hair cells, generating reactive oxygen species and apoptotic cell death that affects high frequencies first. Risk factors include cumulative dose, cranial irradiation, and younger age. Pediatric patients are highly vulnerable, presenting with progressive hearing loss and tinnitus that disrupts language development. Diagnosis relies on serial audiometric monitoring. Sodium thiosulfate is a landmark otoprotectant approved for pediatric patients aged 1 month and older with localized, non-metastatic solid tumors, administered with precise post-cisplatin timing to avoid compromising antitumor efficacy. For adult or metastatic cohorts where systemic chelators are restricted, 2026 protocols actively evaluate localized intratympanic protective gels. Hearing aids and cochlear implants manage established damage under strict audiology-oncology coordination.

Key Highlights

• CIHL is a common, irreversible chemotherapy toxicity with significant long-term impact
• US incidence expected to increase from ~378K to ~398K (~0.5% CAGR)

Market Overview

• Germany market projected to grow from ~$0.7M to ~$1.1M (~4-5% CAGR)
• Market remains small and niche, with growth driven by protective therapies like STS and survivorship care focus

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Sensorion